<DOC>
	<DOCNO>NCT00157027</DOCNO>
	<brief_summary>The objective clinical trial : - Assess safety use extracorporeal photoimmune therapy photosensitize agent Uvadex treatment HIV-1 infection ; - Evaluate effect therapy HIV-1 viral load polymerase chain reaction ( PCR ) analysis ; - Evaluate effect therapy CD4+ , CD8+ cell CD4/CD8 ratio ; - Evaluate effect therapy patient 's immune system , skin reactivity standard anergy panel .</brief_summary>
	<brief_title>RHIV A Pilot Study Refractory Intolerant Highly Active Antiretroviral Therapy ( HAART )</brief_title>
	<detailed_description>Rationale Use ECP UVADEX Patients HIV-1 Infection Studies demonstrate psoralen ultraviolet A light inactivate HIV virus vitro . Edelson , et al , show extracorporeal photochemotherapy ( ECP ) psoralen primarily target CD4+ cell , population predominately affect HIV-1 infection . It postulate re-infusion ECP treat cell fraction , free virus , cell-associated virus along whole cell , cell fragment , soluble antigen , may serve engender specific HIV immune response . A twenty-patient study use ECP psoralen conduct Bisaccia , et al . In study , patient HIV positive enzyme link immunosorbent assay positive result confirm Western blot test . Patients stag Walter Reed class WR3 WR5 . Extracorporeal photoimmune therapy administer two consecutive day monthly basis 6-29 month . This study report CD4 count decline slowly historical control . Walter Reed classification improve 55 % ( 11/20 ) , stable 35 % ( 7/20 ) decline 10 % ( 2/20 ) patient treat study . One measure `` vivo '' evaluation T-cell function provide skin reactivity recall antigen ( DTH ) . A lack response associate progression HIV disease . In Bisaccia study , skin reactivity recall antigen ( DTH ) improve 55 % ( 11/20 ) patient , stable 35 % ( 7/20 ) , progress anergy 5 % ( 1/20 ) . One patient initially anergic remain anergic post-treatment . Following treatment ECP , 60 % ( 9/15 ) , display normal skin test response , whereas baseline examination normal 5 % ( 1/19 ) . In addition , 21 % ( 4/19 ) patient show partial skin test response . Only 10 % ( 2/20 ) patient develop new opportunistic infection . This include patient initially anergic remain anergic patient progress anergy post-ECP treatment . DESCRIPTION OF THE UVAR® XTSÔ PHOTOPHERESIS SYSTEM Photopheresis ( extracorporeal photoimmune therapy [ ECP ] ) process develop THERAKOS , Inc. , Johnson Johnson Company . During process ECP , whole blood drawn patient several cycle , centrifuge separated component plasma , white cell ( buffy coat ) , red blood cell . A portion white cell plasma save separate compartment . The remain plasma red blood cell immediately return patient . The saved buffy coat ( white blood cell ) plasma inoculate photosensitizing agent UVADEX . Photoactivation begin suspension expose prescribed amount ultraviolet-A light . After photoactivation complete , treated suspension return patient . Photopheresis perform use UVAR XTS continuous process . During entire therapy , patient remains connect photopheresis instrument . The duration time completion buffy coat collection reinfusion light-activated buffy coat approximately 30 minute .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Photosensitizing Agents</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>HIV1 positive ELISA assay confirm Western blot Patients must refractory intolerant HAART . Refractory HIV patient define patient meet follow criterion : Resistance major group active agent ( nonnucleotide reverse transcriptase inhibitor [ NNRTIs ] , nucleotide reverse transcriptase inhibitor [ NRTIs ] , protease inhibitor [ PIs ] ) ; Not achieve &lt; 400 copies/mL 24 week &lt; 50 copies/mL 48 week therapy ; Documentation resistance mutation genotype test ; Failure increase CD4+ cell &gt; 25 cells/mm3 baseline one year therapy . HIV RNA &gt; = 3,000 copies/mL PCR analysis CD4 count &gt; 75 cells/mm3 No new antiretroviral agent may add prestudy evaluation , treatment , followup period . Life expectancy &gt; 6 month Able give inform consent comply study visit , procedure , ECP treatment schedule Ages 18 70 Females childbearing potential may lactate must human chorionic gonadotropin ( HCG ) negative study entry agree use acceptable method birth control ( hormonal , intrauterine device , spermicide barrier ) throughout study period . Minimum body weight 88 lb ( 40kg ) May current photosensitive disease systemic lupus erythematosus ( SLE ) porphyria Adequate hematological function absolute neutrophil count &gt; = 500/mm platelet count &gt; = 50,000/mm . Established history heparin psoralen allergy Patients aphakia significantly increase risk retinal damage due absence lens . Patients lens implant acceptable inclusion . Current participation ( within 30 day ) clinical trial examine safety and/or efficacy antiretroviral agent ( ) Patients major illness ( e.g . malignancy , renal failure , severe cardiac disease , severe neurologic disease ) either might preclude completion study bias efficacy assessment . Patients may tolerate extracorporeal volume require procedure , reason severe cardiovascular disease , i.e . history congestive heart failure severe anemia ( hemoglobin &lt; 90 g/L ) Patients photosensitive disease , porphyria systemic lupus erythematosus . Special care must take treatment patient require medication ( either topically systemically ) course study photosensitize potential , phenothiazine , tetracycline , sulfonamide , nonsteroidal antiinflammatory drug ( NSAIDs ) chlorothiazide . Patients must take photosensitizing drug study receive within 24 hour schedule treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV-1 Positive ELISA Assay</keyword>
	<keyword>Confirmed Western Blot</keyword>
	<keyword>Refractory intolerant HAART</keyword>
</DOC>